This sustained expression of surface GARP and GARP transcript levels in ndGBs and recGBs suggests the potential utility of GARP as a reliable GSC biomarker, which persists at different tumor stages, possibly allowing for the detection of potential residual disease of a remarkably invasive cancer type. This evidence concerns the gene LRRC32 and neoplasm.